These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25381643)

  • 1. Genome-wide linkage analysis and tumoral characterization reveal heterogeneity in familial colorectal cancer type X.
    Sánchez-Tomé E; Rivera B; Perea J; Pita G; Rueda D; Mercadillo F; Canal A; Gonzalez-Neira A; Benitez J; Urioste M
    J Gastroenterol; 2015 Jun; 50(6):657-66. PubMed ID: 25381643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial Colorectal Cancer Type X (FCCTX) and the correlation with various genes-A systematic review.
    Nejadtaghi M; Jafari H; Farrokhi E; Samani KG
    Curr Probl Cancer; 2017; 41(6):388-397. PubMed ID: 29096939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study of hereditary non-polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity.
    Warden G; Harnett D; Green J; Wish T; Woods MO; Green R; Dicks E; Rahman P; Zhai G; Parfrey P
    Clin Genet; 2013 Dec; 84(6):522-30. PubMed ID: 23278430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome.
    Klarskov L; Holck S; Bernstein I; Nilbert M
    J Clin Pathol; 2012 Apr; 65(4):352-6. PubMed ID: 22287689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer.
    Therkildsen C; Jönsson G; Dominguez-Valentin M; Nissen A; Rambech E; Halvarsson B; Bernstein I; Borg K; Nilbert M
    Eur J Cancer; 2013 Apr; 49(6):1226-35. PubMed ID: 23245329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial colorectal cancer type X syndrome: two distinct molecular entities?
    Francisco I; Albuquerque C; Lage P; Belo H; Vitoriano I; Filipe B; Claro I; Ferreira S; Rodrigues P; Chaves P; Leitão CN; Pereira AD
    Fam Cancer; 2011 Dec; 10(4):623-31. PubMed ID: 21837511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological differences between familial colorectal cancer type X and sporadic cancer in an isolated area of spain.
    Medina-Arana V; Rahy-Martín A; Delgado-Plasencia L; Martínez-Riera A; León-Ayllón D; Rodríguez-Castellano D; Bravo-Gutiérrez A; Fernández-Peralta A; González-Aguilera JJ
    Colorectal Dis; 2016 Nov; 18(11):O388-O396. PubMed ID: 27671100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
    Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
    Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of familial colorectal cancer Type X, Lynch syndrome, and non-familial colorectal cancer.
    Shiovitz S; Copeland WK; Passarelli MN; Burnett-Hartman AN; Grady WM; Potter JD; Gallinger S; Buchanan DD; Rosty C; Win AK; Jenkins M; Thibodeau SN; Haile R; Baron JA; Marchand LL; Newcomb PA; Lindor NM;
    Br J Cancer; 2014 Jul; 111(3):598-602. PubMed ID: 24918813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
    Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
    Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.